EP2915525

Töflur, sem ekki er hægt að misnota, til notkunar undir tungu sem innihalda búprenórfín og naloxón

  • Status:
    EP einkaleyfi í gildi á Íslandi
  • EP appl. date:
    18.9.2012
  • EP published:
    11.8.2021
  • EP application number:
    15156024.0
  • Max expiry date:
    17.9.2032
  • Expiry date:
    17.9.2026
  • Next due date:
    30.9.2026
  • Title:
    Sublingual abuse-resistant tablets comprising buprenorphine and naloxone

Timeline

Today
18.9.2012EP application
11.8.2021EP Publication
14.9.2021Translation submitted
15.10.2021Registration published
17.9.2026Expires

Owner

  • Name:
    Orexo AB
  • Address:
    Box 303, 751 05 Uppsala, SE

Inventor

  • Name:
    Fischer, Andreas
  • Address:
    SE-751 05 Uppsala, SE

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113, Reykjavík,

Priority

  • Number:
    201161536180 P
  • Date:
    19.9.2011
  • Country:
    US

Classification

  • Categories:
    A61K 9/00, A61K 31/485, A61K 9/20, A61K 31/4748, A61P 25/04, A61P 25/30, A61P 25/36

Annual fees

Number

Paid

Expires

Payer

Number: 10

Paid: 27.9.2021

Expires: 17.9.2022

Payer: Árnason Faktor ehf.

Number: 11

Paid: 27.9.2022

Expires: 17.9.2023

Payer: Árnason Faktor ehf.

Number: 12

Paid: 30.6.2023

Expires: 17.9.2024

Payer: Árnason Faktor ehf.

Number: 13

Paid: 24.9.2024

Expires: 17.9.2025

Payer: Árnason Faktor ehf.

Number: 14

Paid: 20.8.2025

Expires: 17.9.2026

Payer: iPify

Upload documents